Poseida Therapeutics, Inc.
Clinical trials sponsored by Poseida Therapeutics, Inc., explained in plain language.
-
Experimental cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an investigational cell therapy called P-MUC1C-ALLO1 in adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for early sign…
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
15-Year watch begins for myeloma patients treated with experimental cell therapy
Disease control OngoingThis study follows about 100 people with multiple myeloma who have already received the experimental cell therapy P-BCMA-101. Researchers will track them for up to 15 years to check for delayed side effects and see how long the treatment's anti-cancer effects last. The goal is to…
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Engineered donor cells take on Hard-to-Treat lymphomas
Disease control OngoingThis early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New CAR-T therapy aims to control Hard-to-Treat multiple myeloma
Disease control OngoingThis early-stage study tests an experimental therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses donor immune cells engineered to target and kill myeloma cells. The main goals are to check …
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC